ClinicalTrials.gg
RecruitingNCT07517679Updated Jul 20, 2026

Methadone for Post-operative Spine Surgery

A Phase 4 interventional study of Methadone and Standard of care in Pain, Postoperative, sponsored by Brandon Knopp. Recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Brandon Knopp · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies testing methadone in Pain, Postoperative — 8 open to participants now, 8 under way, 3 of them phase 3. Methadone · Pain, Postoperative.

Planned enrollment
31st of 37
30 · median 75
Started
2026
with 4 others
Phase 4
21 of 37
4 open now
Registered
36th of 37
by date
Lead sponsor
1 of 37
Brandon Knopp

Among the 37 studies testing methadone in Pain, Postoperative, this one is the 31st largest by planned enrollment, is one of 5 that started in 2026, is one of 21 in phase 4, and was the 36th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

8 of the 37 studies testing methadone in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methadone

Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing methadone in Pain, Postoperative, or all of them as a file.
02

Study summary

The goal of this prospective cohort study is to evaluate the clinical effects of post-induction methadone on perioperative pain control, opioid requirements, and recovery outcomes in adult patients undergoing elective spine surgery, with the goal of improving postoperative analgesia and enhancing recovery efficiency. The main questions it aims to answer are the perioperative pain control and opioid requirements between the two groups.

Post-induction methadone can offer equivalent or improved pain control following major spine procedures and reduce intra- and postoperative opioid requirements, improve perioperative pain control and shorten PACU stay.

Researchers will compare perioperative opioid use (morphine equivalents (ME), during the intraoperative and postoperative periods (PACU and 24-hour totals) between the standard intraoperative opioid regimen group and the methadone group.

Patients will be randomized preoperatively to one of two groups: (both groups will receive additional multimodal pain control including opioids, not including methadone, as needed) Standard intraoperative opioid regimen (control) Methadone 0.2 mg/kg (max 20 mg)

If the patient is in the methadone group, the patient will receive a predetermined dose of Methadone (0.2mg/kg) intravenously after induction (they are given medications to sleep for surgery). They will proceed with surgery, and all patients will receive standard of care management regardless of whether they receive Methadone or not. Following the surgery, all study participants will be asked at set times about their pain level and, 24 hours after the surgery, will be asked if they are satisfied with their pain management for the surgery. Data regarding their clinical progression and pain control/pain medication requirements will be collected for the duration of the hospitalization.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • methadone
  • opioids
  • spine surgery
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing elective spine surgery (e.g., fusion, decompression)
  • Expected postoperative inpatient admission
  • Able to provide
  • Patients with opioid use disorder (OUD) may be included if on stable maintenance therapy

Exclusion criteria

Exclusion Criteria:

  • Use of regional or neuraxial anesthesia
  • to methadone use (e.g., prolonged , allergy, severe hepatic disease)
  • Cognitive impairment precluding consent or accurate pain scoring
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Methadone

    Drug: Methadone

  • Active comparator
    Standard of care

    Drug: Standard of care

Interventions

  • Methadone 0.2 mg/kg (max 20 mg)

  • DrugStandard of care

    Standard intraoperative opioid regimen (control)

06

What researchers measure

Primary outcomes

  1. Perioperative Opioid use in morphine equivalents (ME)

    perioperative opioid use (morphine equivalents (ME): intraoperative, PACU, and 72-hour totals)

    Time frame: Perioperative until 72 hours postoperative

Secondary outcomes

  1. Change in numeric rating scale (NRS) pain scores

    Pain scores recorded in the electronic medical record (EMR) using the NRS scale 0-10. A higher score indicates greater pain level. Will track scores over first 24 hours following surgery completion (as determined by PACU arrival)

    Time frame: PACU arrival to 24 hours postoperative

  2. Time in PACU

    Will measure duration of time patient spends in the PACU (measured in hours)

    Time frame: PACU arrival to PACU discharge (determined by time of PACU discharge note entry). Assess up to 24 hours postoperatively.

  3. Hospital Length of Stay

    Duration of time the patient spends in the hospital. Measured in days

    Time frame: Hospital admission to hospital discharge. Measured in days and determined as the time from admission for surgery to hospital discharge. Assess up to 30 days postoperatively

  4. Incidence of respiratory depression

    The incidence of respiratory depression would be defined by any of the following: * respiratory rate \< 10 breaths/min for \>5 min * SpO₂ \< 90% for \>5 min (SpO₂ \<88% if history of COPD) * PaCO₂ \> 50 mmHg AND increased more than 20% of baseline (if baseline known) * Naloxone use postoperatively The following events will be documented in the electronic medical record (EMR) and study personnel will chart review for documented incidence of the criteria above and report findings. Will be reported as a "yes" or "no".

    Time frame: Measured from time of PACU admission until 72 hours postoperatively.

  5. Incidence of Postoperative nausea and vomiting

    Incidence of postoperative nausea or vomiting will be recorded in the electronic medical record (EMR) and study personnel will chart review for documented incidence of postoperative nausea or vomiting during the first 72 hours postoperatively.

    Time frame: Assessed postoperatively up to 72 hours after documented PACU admission time

  6. Patient Satisfaction

    Patient satisfaction survey will be administered by study staff 24 hours postoperatively to measure the patient satisfaction of their postoperative pain management. The survey will measure the following over the 24 postoperatively: the patients pain level on a scale from 1-10, their pain control adequacy from very poorly to very well, functional impact on getting out of bed, walking, deep breathing/coughing, physical therapy, sleeping or none, side effects of opioids including: nausea, vomiting, itching, constipation, excessive sleepiness, dizziness, or confusion, and their satisfaction level of pain management from very dissatisfied to very satisfied.

    Time frame: Postoperative until 24 hours postoperative

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Apr 2027, 10 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 10 months is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 8, 2026
StartActual
Jun 10, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07517679
Lead sponsor
Brandon Knopp
Responsible party
Brandon Knopp (Principal Investigator, University of Kentucky) — Sponsor-investigator
First posted
Apr 8, 2026
Start date
Jun 10, 2026
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jul 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion